{'fraction_non_alphanumeric': 0.033277870216306155, 'fraction_numerical': 0.0016638935108153079, 'mean_word_length': 5.994186046511628, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Raspberry ketone: an emerging molecule for treating depression and associated symptoms - molecular docking and pharmacokinetics studies

After analyzing multiple pharmaceutical databases like ScienceDirect, PubMed, Google Scholar, and others, it was discovered that RK has yet to be linked to any anti-depressant action. The primary goal of this work was to use in-silico techniques to investigate the anti-depressant capability of RK against three major targets (monoamine oxidases, MAOs; human serotonin transporter, SERT; and serotonin receptors, 5HTs). Moreover, prediction of drug-likeliness, bioavailability, and pharmacokinetics of RK has been done using online computational tools (SwissADME, SwissTargetPrediction, and SwissBioisostere). Thein silico study indicated the emerging role of RK in the management of clinical depression. The pharmacokinetic studies, target prediction studies against 3 species, and biosisosteric-based studies also supported the possibilities of lead development. The study will open new avenues of application of this low-molecular-weight-ligand (LMWL) for the clinicians, chemists, and other scientific professionals in context to emerging depression challenges.